Text Size

Incidence of Methicillin Resistant Staphylococcus Aureus (MRSA) Carriage Rates in Resident Physicians

This study has been terminated.
(Minimal enrollment)
Sponsor:
Information provided by (Responsible Party):
Gary Kinasewitz, University of Oklahoma
ClinicalTrials.gov Identifier:
NCT00929435
First received: June 24, 2009
Last updated: April 5, 2012
Last verified: April 2012
History of Changes
  Purpose

One hundred new residents will be recruited prior to the start of residency and followed prospectively for a year. Monthly nasal swabs will be performed to identify colonization with methicillin resistant staphylococcus aureus (MRSA).The proportion of study subjects colonized with MRSA at the end of 1 year will be calculated.


Condition
MRSA Colonization

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Incidence of Methicillin Resistant Staphylococcus Aureus (MRSA) Nasal Carriage Among Resident Physicians

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Oklahoma:

Primary Outcome Measures:
  • To detect an increase in MRSA nasal carriage rate among newly appointed residents after 1 year of regular patient contact. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 30
Study Start Date: June 2009
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
MRSA surveillance
Newly recruited resident physicians will be monitored for a year with nasal swabs monthly.

Detailed Description:

This is a prospective observational study looking at the incidence of MRSA colonization. New residents will be monitored every month with nasal swabs.We would like to elucidate factors responsible for MRSA colonization in healthcare workers.We would like to see if health care workers who are colonized spontaneously cleared MRSA and if there was any factors involved.

Nasal swabs will be plated on the spot by trained individuals and the plates then incubated for 48 hours. Plates will be read by microbiologist after incubation.

  Eligibility

Ages Eligible for Study:   25 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

All newly recruited residents will be eligible for enrollment.

Criteria

Inclusion Criteria:

  • Study subjects will be newly appointed residents at the OU medical center

Exclusion Criteria:

  • Previous MRSA infection
  • Current use of mupirocin
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00929435

Locations
United States, Oklahoma
Oklahoma University health science center
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
University of Oklahoma
Investigators
Principal Investigator: Gary T Kinasewitz, MD University of Oklahoma
  More Information

No publications provided

Responsible Party: Gary Kinasewitz, Principal Investigator, University of Oklahoma
ClinicalTrials.gov Identifier: NCT00929435     History of Changes
Other Study ID Numbers: 14684
Study First Received: June 24, 2009
Last Updated: April 5, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of Oklahoma:
MRSA
Contact isolation
Incidence

Additional relevant MeSH terms:
Staphylococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Methicillin
 Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 18, 2013